SpyGlass Pharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is +16.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 3.5% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 30.78
- Open
- 30.12
- Day range
- 29.07 - 31.73
- Avg price
- 30.88
- Volume
- 108.91K
- Turnover
- 3.36M
- Turnover ratei
- 1.68%
- Volume ratioi
- 0.98
- Amplitudei
- 8.66%
- 52-week rangei
- 17.06 - 39.92
Valuation
- P/Ei
- -25.51
- P/E (TTM)i
- -14.44
- P/Bi
- 4.84
- EPSi
- -1.19
- Book value / shi
- 6.29
- Net profit
- -39.92M
- Net assets
- 210.44M
Share structure
- Market cap
- 1.02B
- Float capi
- 197.69M
- Shares out
- 33.46M
- Float sharesi
- 6.50M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-02-06
23.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+79.12K net over the window
Short interest
- Shares short
- 1.16M
- % of floati
- 3.47%
- Days to coveri
- 12.05
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of SpyGlass Pharma (SGP)?
SpyGlass Pharma last traded at 30.43. This page shows a periodic quote snapshot. Check the displayed quote time.
What is SpyGlass Pharma's market cap?
About 1.02B.
What is the P/E ratio of SpyGlass Pharma?
The trailing twelve-month P/E is -14.44. The Valuation tab shows it against the stock's own five-year range.
Does SpyGlass Pharma pay a dividend?
SpyGlass Pharma does not currently pay a regular dividend.
Is SpyGlass Pharma a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 44.00, which implies 44.6% upside from the current price. This is not investment advice.
What is SpyGlass Pharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates SpyGlass Pharma a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
SpyGlass Pharma discussion 0 comments